Beam Therapeutics (NASDAQ: BEAM) insider to sell 25,000 shares
Filing Impact
Filing Sentiment
Form Type
144
Rhea-AI Filing Summary
Beam Therapeutics filed a Form 144 notice for a planned insider stock sale. The filing covers a proposed sale of 25,000 shares of common stock with an aggregate market value of $734,582.50 through Morgan Stanley Smith Barney LLC on the NASDAQ, with an approximate sale date of 01/29/2026.
The 25,000 shares were acquired on 01/29/2026 by exercising stock options directly from the issuer and paid for in cash. Shares of Beam Therapeutics outstanding were 101,474,944 at the time referenced, providing a baseline for the size of this planned sale.
Positive
- None.
Negative
- None.
FAQ
What does Beam (BEAM) disclose in this Form 144 filing?
Beam discloses a planned resale of 25,000 common shares under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ with an approximate sale date of 01/29/2026 and a stated market value of $734,582.50.
What representation does the seller make in this Beam (BEAM) Form 144?
The seller represents that they do not know any material adverse, non-public information about Beam’s current or prospective operations. This representation is a standard Rule 144 requirement tied to the good-faith nature of insider resale transactions.